Kymera Therapeutics Inc. (KYMR): Price and Financial Metrics


Kymera Therapeutics Inc. (KYMR): $36.85

1.37 (+3.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KYMR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KYMR Stock Price Chart Interactive Chart >

Price chart for KYMR

KYMR Price/Volume Stats

Current price $36.85 52-week high $46.22
Prev. close $35.48 52-week low $13.15
Day low $34.68 Volume 549,278
Day high $37.60 Avg. volume 671,128
50-day MA $29.25 Dividend yield N/A
200-day MA $25.62 Market Cap 2.02B

Kymera Therapeutics Inc. (KYMR) Company Bio


Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.


KYMR Latest News Stream


Event/Time News Detail
Loading, please wait...

KYMR Latest Social Stream


Loading social stream, please wait...

View Full KYMR Social Stream

Latest KYMR News From Around the Web

Below are the latest news stories about KYMERA THERAPEUTICS INC that investors may wish to consider to help them evaluate KYMR as an investment opportunity.

It would be worthwhile to take a closer look at Kymera Therapeutics Inc. (KYMR)

Kymera Therapeutics Inc. (NASDAQ:KYMR) marked $35.58 per share on Monday, up from a previous closing price of $35.00. While Kymera Therapeutics Inc. has overperformed by 1.66%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KYMR fell by -10.58%, with highs and lows ranging from $46.22 to […]

US Post News | January 24, 2023

Kymera: Data Derisks Platform, But I Will Wait For More (NASDAQ:KYMR)

Kymera Therapeutics, Inc.''s KT-474 HS/AD data derisked the IRAK4 protein degradation platform, as did Sanofi''s partnering. Click here for what this means for KYMR.

Seeking Alpha | January 23, 2023

Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Yahoo | January 23, 2023

The Kymera Therapeutics Inc. (KYMR) had a good session last reading, didn’t it?

A share of Kymera Therapeutics Inc. (NASDAQ:KYMR) closed at $34.62 per share on Tuesday, up from $34.54 day before. While Kymera Therapeutics Inc. has overperformed by 0.23%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KYMR fell by -18.88%, with highs and lows ranging from $46.22 […]

US Post News | January 18, 2023

Attention Investors: What’s Really Going On With Kymera Therapeutics Inc. (NASDAQ: KYMR)

The trading price of Kymera Therapeutics Inc. (NASDAQ:KYMR) closed higher on Friday, January 13, closing at $34.54, 2.86% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $32.61 and $34.99. In examining the 52-week price action we see that the stock hit a 52-week … Attention Investors: What’s Really Going On With Kymera Therapeutics Inc. (NASDAQ: KYMR) Read More »

Stocks Register | January 17, 2023

Read More 'KYMR' Stories Here

KYMR Price Returns

1-mo 50.53%
3-mo 22.87%
6-mo 67.27%
1-year -0.73%
3-year N/A
5-year N/A
YTD 47.64%
2022 -60.69%
2021 2.40%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7024 seconds.